| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FIL1d |
| Uniprot No | Q9UBH0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-155aa |
| 氨基酸序列 | VLSGALCFRM KDSALKVLYL HNNQLLAGGL HAGKVIKGEE ISVVPNRWLD ASLSPVILGV QGGSQCLSCG VGQEPTLTLE PVNIMELYLG AKESKSFTFY RRDMGLTSSF ESAAYPGWFL CTVPEADQPV RLTQLPENGG WNAPITDFYF QQCD |
| 预测分子量 | 16.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FIL1d重组蛋白的虚构参考文献示例(请注意，FIL1d重组蛋白的名称可能是假设的，实际文献需通过学术数据库查询)：
1. **文献名称**: "Structural and Functional Characterization of Recombinant FIL1d Protein in Plant Immunity"
**作者**: Zhang L. et al.
**摘要**: 本研究解析了FIL1d重组蛋白的晶体结构，发现其通过激活MAPK信号通路增强植物对真菌病原体的抗性，为开发新型抗病蛋白提供了理论基础。
2. **文献名称**: "FIL1d Recombinant Protein Enhances Wound Healing in Mammalian Models"
**作者**: Smith J.R., Patel K.
**摘要**: 通过体外和小鼠实验，证明FIL1d重组蛋白能显著促进成纤维细胞迁移和胶原沉积，提示其作为创伤修复治疗剂的潜力。
3. **文献名称**: "Optimization of FIL1d Expression in E. coli for Industrial-scale Production"
**作者**: Gupta S. et al.
**摘要**: 开发了一种高效的大肠杆菌表达系统，通过密码子优化和发酵条件调控，使FIL1d重组蛋白产量提高3倍，降低了工业化生产成本。
4. **文献名称**: "FIL1d Recombinant Protein as a Novel Biomarker for Early Cancer Detection"
**作者**: Tanaka M. et al.
**摘要**: 在血清学筛选中发现FIL1d重组蛋白与多种癌症(如结直肠癌、乳腺癌)早期阶段显著相关，特异性达92%，具有临床诊断价值。
---
**提示**：以上为模拟文献，实际研究中请通过PubMed、ScienceDirect等平台检索真实文献(关键词：FIL1d recombinant protein + 研究领域)。若FIL1d为特定领域蛋白(如植物免疫、肿瘤学)，建议补充背景信息以缩小检索范围。
FIL1d recombinant protein is an engineered protein derivative designed to mimic or enhance specific functional domains of native proteins involved in cellular adhesion, signaling, or extracellular matrix (ECM) interactions. The "FIL1" designation typically refers to fibrinogen-like or fibronectin-related domains, which are critical in mediating cell-surface interactions, wound healing, and tissue remodeling. The "d" suffix often indicates a modified or truncated version optimized for stability, solubility, or targeted activity.
Originally derived from fibrinogen or related ECM proteins, FIL1d retains conserved binding motifs that interact with integrins, growth factor receptors, or other ECM components. This makes it valuable in biomedical research for studying cell migration, angiogenesis, or regenerative processes. Its recombinant production involves cloning the gene encoding the functional domain into bacterial or mammalian expression systems, followed by purification using affinity chromatography. This ensures high purity and reproducibility, addressing challenges associated with isolating native proteins from biological sources.
FIL1d has applications in tissue engineering, where it serves as a scaffold component to promote cell attachment and differentiation. It is also used in drug delivery systems to enhance targeting or biocompatibility. In disease models, FIL1d helps investigate pathologies linked to ECM dysregulation, such as fibrosis, cancer metastasis, or chronic inflammation. Recent studies explore its potential in 3D cell culture systems to better replicate in vivo microenvironments.
Despite its utility, limitations include potential immunogenicity in therapeutic contexts and variability in post-translational modifications depending on the expression host. Ongoing research focuses on engineering hybrid proteins or PEGylation to improve functionality and reduce adverse effects. As a tool, FIL1d exemplifies the convergence of protein engineering and translational medicine, offering insights into both fundamental biology and clinical applications.
×
